You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 91 No. 2, February 1965 TABLE OF CONTENTS
  Archives
  •  Online Features
  THERAPY
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (6)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical Evaluation of 16-Epiestriol-3-Allyl Ether in Acne Vulgaris

A Collaborative Study

FREDERIC T. BECKER, MD; SEYMOUR B. BRONSTEIN, MD; COLEMAN JACOBSON, MD; PAUL LAZAR, MD; J. FREDERICK MULLINS, MD; ORVILLE STONE, MD; ASHTON WELSH, MD

Arch Dermatol. 1965;91(2):155-158.


Abstract

This is a collaborative report on the efficacy of 16-epiestriol-3-allyl ether in the treatment of acne. A double-blind study of this weak estrogenic compound, as compared with a placebo, was undertaken by five investigators. Essentially identical protocols were followed in the five studies. An attempt was made to control the variables except for the agents being evaluated. The results were based on the effect of the estrogen on the lesions of acne as well as on the oiliness of the skin.

The results in 134 patients with recalcitrant acne are reported. Sixty-six received 16-epiestriol-3-allyl ether and 68 placebo. The compound 16-epiestriol-3-allyl ether in oral doses of 15, 30, and 45 mg daily, for three successive four-week periods failed to show any superiority over placebo either in improvement of acne or in reduction of skin oiliness. Fifty-three per cent of those receiving 16-epiestriol-3-allyl ether and 50% of those receiving placebo showed improvement in acne. Fifty-five per cent of those receiving medication and 49% of those receiving placebo showed an estimated reduction in oiliness of the skin.

The significance of this high percentage of placebo response even in recalcitrant acne in the evaluation of the efficacy of agents in this field is discussed. A brief review of the etiologic and therapeutic relationships of hormonal factors in acne is also presented.

These results are consistent with the report that this compound failed to suppress sebum production determined gravimetrically in adult males.



Author Affiliations

DULUTH, MINN; MORRIS PLAINS, NJ; DALLAS; HIGHLAND PARK, ILL; GALVESTON, TEX; CINCINNATI

From the Department of Dermatology, Duluth Clinic (Dr. Becker); Division of Clinical Research, Warner-Lambert Research Institute, Morris Plains, NJ (Dr. Bronstein); Department of Dermatology, University of Texas, Medical Branch (Drs. Mullins and Stone).


Footnotes

Submitted for publication May 1, 1964.

Reprint requests to Duluth Clinic, Duluth, Minn 55802. {dagger} Deceased.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antibiotics and the Placebo Reaction in Acne
Savin and Turner
JAMA 1966;196:365-367.
ABSTRACT  

The Response of Acne to Placebos and Antibiotics
Crounse
JAMA 1965;193:906-910.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1965 American Medical Association. All Rights Reserved.